Karthik Ramasamy

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 231 citations · Full text

Regenerative Medicine, Cell Therapy, Transplantation +7

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Sarah Gooding, Naser Ansari‐Pour, Fadi Towfic et al. · Blood · 2020 · 151 citations · Full text

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

Meletios Α. Dimopoulos, Katja Weisel, Niels W.C.J. van de Donk et al. · Journal of Clinical Oncology · 2018 · 71 citations · Full text

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Paul G. Richardson, Suzanne Trudel, Rakesh Popat et al. · New England Journal of Medicine · 2023 · 68 citations · Full text